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Introduction: Fibromyalgia (FM) is a rheumatic condition characterized by a picture of gener-
alized chronic pain, hyperalgesia, and allodynia. Symptoms such as fatigue, sleep disorders, 
morning stiffness, headache, and paresthesia can also be present. It is also associated with 
other comorbidities, such as depression, anxiety, irritable bowel syndrome, myofascial pain 
syndrome, and nonspecific urethral syndrome. Few studies have addressed the evolution 
of FM, especially regarding medium- and long-term evolution, such as why some patients 
fare better than others, despite being submitted to the same treatment.
Objective: To determine whether there is a correlation between demographic and clinical 
variables and FM severity.
Material and methods: Sixty women who met the 1990 FM classification criteria of the Ameri-
can College of Rheumatology were divided into three groups, according to the severity es-
tablished by the Fibromyalgia Impact Questionnaire (FIQ): mild (0 to 50), moderate (50 to 
70), and severe (70-100). 
Results: Nine demographic and clinical variables were assessed; a significant difference (p 
< 0.05) was observed only in the groups showing higher FIQ scores with the presence of 
depression and workers’ compensation interests. 
Conclusion: The impact of FM measured by the FIQ is directly correlated with the severity of 
depression and the presence of workers’ compensation interests. 
© 2013 Elsevier Editora Ltda. All rights reserved.
Correlação entre variáveis demográficas e clínicas, e a gravidade da 
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Introdução: A fibromialgia (FM) é uma condição reumatológica que se caracteriza por um 
quadro de dor crônica generalizada, hiperalgesia e alodinia. Podem estar presentes sinto-
mas como fadiga, distúrbios do sono, rigidez matinal, cefaleia e parestesias. Também está 
associada a outras comorbidades, como depressão, ansiedade, síndrome do intestino irritá-
vel, síndrome miofascial e síndrome uretral inespecífica. Poucos trabalhos têm abordado a 
evolução da FM, em especial em relação a médio e longo prazo. Por que alguns pacientes se 
saem melhor do que outros, apesar de serem submetidos ao mesmo tratamento?
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Objetivo: Determinar se há correlação entre variáveis demográficas e clínicas, e a gravidade 
da FM.
Material e métodos: Sessenta mulheres que preencheram os critérios de classificação para 
FM do American College of Rheumatology de 1990 foram divididas em três grupos, de acor-
do com a gravidade estabelecida pelo Questionário de Impacto da Fibromialgia (FIQ): severa 
(70-100); moderada (50-70) e leve (0-50). 
Resultados: Foram analisadas nove variáveis demográficas e clínicas, sendo observada dife-
rença significativa (P < 0,05) apenas nos grupos de maiores escores do FIQ, com a presença 
de depressão e interesses trabalhistas.
Conclusão: O impacto da FM medido pelo FIQ se correlaciona diretamente com a intensida-
de da depressão e a presença de interesses trabalhistas.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Fibromyalgia (FM) is a rheumatic condition characterized by 
chronic generalized pain, hyperalgesia, and allodynia. Symp-
toms such as fatigue, sleep disorders, morning stiffness, 
headache, and paresthesia can also be present.1 It is also as-
sociated with other comorbidities, such as depression, anxi-
ety, irritable bowel syndrome, myofascial pain syndrome, and 
nonspecific urethral syndrome.2 
This syndrome has an etiology and pathogenesis that are 
yet to be fully clarified, and the basis of its physiopathology 
is the amplification of painful stimulus transmission, altering 
the perception of pain.1,3 Although few Brazilian epidemiologi-
cal studies have been published, its prevalence is estimated at 
around 2.5% in the adult Brazilian population. The vast major-
ity of patients are female and aged between 35 and 44 years.2,4
The negative impact of FM on quality of life has been well 
established by qualitative and quantitative studies.5,6 This 
impact is global and involves personal issues such as diffi-
culty to perform professional or everyday tasks, uncertainty 
regarding personal performance, and reduced quality of work, 
with consequent effects on work, family and social life, and 
even family income.7 
The treatment should be multidisciplinary, with a drug 
and non-drug therapy combination tailored to each patient’s 
needs.1
Few studies have addressed the evolution of FM, especially 
regarding medium and long-term evolution. The literature re-
ports symptom stability over time.8,9 The possible causes of 
this stability can be found in the syndrome itself or in the 
ineffectiveness of the recommended therapeutic measures to 
date.10 
Although the musculoskeletal complaint is the most prev-
alent, the non-evolution to deformities leads to the conclu-
sion that the disability is due to pain and fatigue.11 Since the 
therapy is ineffective in the long-term control of symptoms, 
the stability in the degree of disability is somewhat expected. 
It is noteworthy that, despite treatment failure, most patients 
remain in treatment, focusing on improving quality of life.10
Why do some patients evolve better than others, despite 
being submitted to the same treatment? Why is symptom in-
tensity and its impact on daily life so variable? Which aspects 
influence this diversity? These questions have not been fully 
answered yet. The aim of this study was to determine wheth-
er there is a correlation between demographic and clinical 
variables and FM severity, when measured by its impact on 
quality of life using the Fibromyalgia Impact Questionnaire 
(FIQ).  
The aim of this study was to determine whether there is a 
correlation between demographic and clinical variables and 
the impact of FM. 
Material and methods
Drawing
This was an epidemiological, descriptive, and cross-sectional 
study of patients from the outpatient rheumatology clinic of 
the Conjunto Hospitalar de Sorocaba (CHS), Sorocaba, Brazil.
Casuistry
The sample consisted of female patients who met the 1990 
fibromyalgia classification criteria of the American College of 
Rheumatology (ACR) and were treated in outpatient rheuma-
tology clinic of the CHS.
Data collection tools and variables 
Data were obtained from the patients’ files and through in-
terviews conducted during the application of the assessment 
tools for the following variables:
1 – duration of the disease (symptom onset);
2 – age at onset;
4 – family income;
7 –previous diagnosis of depression;
8 – presence of workers’ compensation interests (sick 
leave, retirement, accident at work, labor claims);
11 – clinical concomitant diseases;
12 – osteoarticular concomitant diseases;
13 – impact on quality of life measured by the FIQ;
14 – pain intensity measured by the visual analog scale 
(VAS);
15 – severity of depression assessed by the Beck Depres-
sion Inventory (BDI).
462 R E V  B R A S  R E U M A T O L .  2 0 1 3 ; 5 3 ( 6 ) : 4 6 0 – 4 6 3
16 - intensity of anxiety perception.
Demographic and clinical data were obtained using a  spe-
cific questionnaire. The intensity of pain, anxiety, and other 
symptoms were measured by the numeric analog scale. This 
scale ranges from 0 to 10 – where0 indicates absence of the 
symptom and 10 represents the maximum possible intensity. 
Depression was assessed by the BDI. This scale consists of 
21 self-administered, multiple-choice questions, which can de-
termine the degree of depression. It comprises questions re-
garding the patients’ perception of their state of joy or sorrow, 
failure and guilt, and questions about their decision-making 
abilities, interest in people, health concerns, and sexual drive.  
The presence of workers’ compensation interests was de-
fined as  receiving sick leave from the Brazilian Institute of 
Social Security or tetirement due to disability. 
The impact on quality of life was measured by the FIQ 
questionnaire, consisting of ten items that assess the impact 
of FM on functional capacity and professional activities, and 
that quantifies the main symptoms. The FIQ has a score rang-
ing from 0 to 100, with 0 corresponding to no impact and 100 
to maximum impact. 
Patients were divided into three groups, according to the 
FIQ total score:
Group A – 0 to 50 (mild impact);
Group – 50 to 70 (moderate impact);
Group C – 70 to 100 (severe impact).
Demographic and clinical data were described as mean 
and standard deviation, or as number and percentage of pres-
ence of the studied variable. Association tests (chi-squared 
or Fisher’s exact test) were performed between the different 
variables studied and subgroups, as well as tests (Student’s 
t-test, analysis of variance [ANOVA]) to compare between the 
different quantitative variables studied and the subgroups. 
Results 
Table 1 presents the demographic data. No difference was 
observed among the three groups for any of the studied vari-
ables. There was a statistically significant difference in the 
isolated comparison of groups A and B regarding the presence 
of workers’ compensation interests.
Table 2 shows the comparisons among the groups regard-
ing the clinical variables. A significant difference was ob-
served only for the presence of depressive symptoms in the 
groups with greater impact on quality of life. 
Discussion
The analysis of demographic data disclosed no statistically 
significant difference among the groups, and demonstrated 
that they were matched for age, symptom onset, family in-
come, education, and presence of workers’ compensation in-
terests, among others.
A significant difference was observed regarding the pres-
ence of workers’ compensation interests when comparing the 
groups with greater impact with the group with mild impact. 
This result was somehow expected, since cessation of work 
implies a greater impact of the disease. 
The patients had a mean age of 48.6 years. The mean age 
of symptom onset was 36 years. This finding is higher than 
those observed in other studies.12,13 The service where this 
study was conducted is tertiary and has a series that cannot be 
generalized to the entire population of fibromyalgia patients. 
The mean age of onset was compatible with other studies, in 
which this variable ranged between 12 and 55 years.14 
Regarding family income, the patients had a mean of 1.4 
Brazilian minimum wages - slightly below the value described 
by Costa et al.,15 i.e., between 1.5 and 2.0 Brazilian minimum 
wages. The level of education in the present sample was simi-
lar to that in the studies by Berber et al.13 and Martins et al.16
Table 2 – Comparison among the groups regarding 
clinical variables.
Variable/Group (A) (B) (C) P
Duration  
(mean and SD) 
10.7 (8.1) 7.9 (6.2) 13.3 (10.1) 0.13
Interval between 
symptom onset 
and diagnosis 
(mean and SD)
5.7 (7.4) 5.8 (7.4) 4.9 (5.6) 0.91
Intensity of pain 
(mean and SD)
8.1 (2.1) 8.4 (1.7) 9.2 (1.2) 0.13
Depression index 
(mean and SD)
14.6 (7.0)a 26.4 (12.6)b 28.7 (13.1)b < 0.001
Presence of other clinical diseases (n, %)
Yes 12 (20.3) 19 (32.2) 12 (20.3) 0.08
Presence of other rheumatic diseases (n,%)
Yes 15 (25.4) 12 (20.3) 11 (18.6) 0.27
Duration of 
treatment  
(years, SD)
5.8 (7.1) 4.6 (3.5) 5.9 (4.1) 0.68
Previous diagnosis of depression (n, %)
Yes 8 (14.3) 15 (26.8) 13 (23.2) 0.10
SD, standard deviation; n, number. 
Table 1 – Comparação entre os grupos em relação às 
variáveis demográficas.
Variable/Group (A) (B)  (C) P
Age (mean, SD) 49.7 (7.7) 49.6 (7.7) 46.7 (10.2) 0.47
Age at onset (mean, 
SD)
36.9 (11.5) 35.4 (14.6) 35.8 (11.1) 0.93
Family incomea 1,807.63 
(1,233.65)
1,336.85 
(993.55)
1,175.79 
(1,004.58)
0.18
Schooling (n, %)
Group I 13 (23.6) 9 (16.4) 13 (23.6) 0.42b 
Group II 4 (7.3) 8 (14.6) 2 (3.6)
Group III 1 (1.8) 2 (3.6) 1 (1.8)
Group IV 1 (1.8) 0 (0.0) 1 (1.8)
Workers’ 
compensation 
interests (n, %)
Yes 6 (11.8) 11 (21.6) 11 (21.6) 0.07
SD, standard deviation; n, number.
aMean family income (Brazilian reais).
bP-value estimation calculated by Monte Carlo simulation.
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The analysis of clinical variables demonstrated a mean du-
ration of disease of 126 months, higher than the mean found 
in another study by the authors, conducted in 2006.14 The time 
to diagnosis was 65 months (> 5 years) in the present study 
study. This interval was higher than that reported by Berber et 
al.13 and Martins et al.,16 who showed a time interval < 2 years. 
Regarding the intensity of pain, the patients studied had a 
mean of 8.5, slightly higher than that reported in literature.17 
The most significant finding was the association between 
the intensity of depressive symptoms and FM impact. The hy-
pothesis that patients with emotional disorders would con-
stitute a subgroup with greater severity has already been pre-
sented in the medical literature. Santos et al.18 concluded that a 
group of FM patients had worse quality of life and higher levels 
of depression when compared with a control group, suggesting 
an association between FM and depression, and that this could 
be regarded as a secondary symptom of the syndrome. 
Giesecke et al. proposed the distribution of fibromyalgia 
patients into subgroups based on pain sensitivity and vari-
ous emotional factors that included affective disorders. Ac-
cording to the authors, the groups with increased pain sen-
sitivity and poor self-control over their symptoms included 
patients with higher levels of mood disorders.19 The current 
study supported the hypothesis that the presence of depres-
sion is a more important factor that the other variables. Oth-
er authors have associated higher pain intensity with the 
presence of depression.20 
The presence of other diseases associated with FM did not 
reach statistical significance, although they were present in 
all three groups (64.3% to 72.8%). Ribeiro et al.21 found a high 
prevalence of active comorbidities associated with FM (4.05 
per patient). 
Therefore, it is concluded that the level of depression and 
presence of workers’ compensation interests are correlated 
with the impact of FM, and may be prognostic factors. 
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